Top

Published in:

Open Access 01-12-2011 | Research article

Racial variation in lipoprotein-associated phospholipase A₂in older adults

Authors: Keane K Lee, Stephen P Fortmann, Ann Varady, Joan M Fair, Alan S Go, Thomas Quertermous, Mark A Hlatky, Carlos Iribarren

Published in: BMC Cardiovascular Disorders | Issue 1/2011

Abstract

Background

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) is a predictor of cardiovascular events that has been shown to vary with race. The objective of this study was to examine factors associated with this racial variation.

Methods

We measured Lp-PLA₂ mass and activity in 714 healthy older adults with no clinical coronary heart disease and not taking dyslipidemia medication. We evaluated the association between race and Lp-PLA₂ mass and activity levels after adjustment for various covariates using multivariable linear regression. These covariates included age, sex, diabetes, hypertension, body mass index, lipid measurements, C-reactive protein, smoking status, physical activity, diet, income, and education level. We further examined genetic covariates that included three single nucleotide polymorphisms shown to be associated with Lp-PLA₂ activity levels.

Results

The mean age was 66 years. Whites had the highest Lp-PLA₂ mass and activity levels, followed by Hispanics and Asians, and then African-Americans; in age and sex adjusted analyses, these differences were significant for each non-White race as compared to Whites (p < 0.0001). For example, African-Americans were predicted to have a 55.0 ng/ml lower Lp-PLA₂ mass and 24.7 nmol/ml-min lower activity, compared with Whites, independent of age and sex (p < 0.0001). After adjustment for all covariates, race remained significantly correlated with Lp-PLA₂ mass and activity levels (p < 0.001) with African-Americans having 44.8 ng/ml lower Lp-PLA₂ mass and 17.3 nmol/ml-min lower activity compared with Whites (p < 0.0001).

Conclusion

Biological, lifestyle, demographic, and select genetic factors do not appear to explain variations in Lp-PLA₂ mass and activity levels between Whites and non-Whites, suggesting that Lp-PLA₂ mass and activity levels may need to be interpreted differently for various races.

Available only for authorised users

Corson MA, Jones PH, Davidson MH: Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008, 101: 41F-50F. 10.1016/j.amjcard.2008.04.018.CrossRefPubMed

Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F: Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007, 82: 159-65. 10.4065/82.2.159.CrossRefPubMed

Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004, 109: 837-42. 10.1161/01.CIR.0000116763.91992.F1.CrossRefPubMed

Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C: Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004, 110: 1903-8. 10.1161/01.CIR.0000143377.53389.C8.CrossRefPubMed

Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005, 111: 570-5. 10.1161/01.CIR.0000154553.12214.CD.CrossRefPubMed

Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000, 343: 1148-55. 10.1056/NEJM200010193431603.CrossRefPubMed

Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005, 165: 2479-84. 10.1001/archinte.165.21.2479.CrossRefPubMed

Iribarren C: Lipoprotein-Associated Phospholipase A2 and C-Reactive Protein for Measurement of Inflammatory Risk: Independent or Complementary?. Cardiovascular Risk Reports. 2010

Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J: Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010, 375: 1536-44.CrossRefPubMed

10.

White H, Held C, Stewart R, Watson D, Harrington R, Budaj A, Steg PG, Cannon CP, Krug-Gourley S, Wittes J, Trivedi T, Tarka E, Wallentin L: Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J. 2010, 160: 655-61. 10.1016/j.ahj.2010.07.006.CrossRefPubMed

11.

Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, Murphy SA, de Lemos JA: Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis. 2008, 199: 110-5. 10.1016/j.atherosclerosis.2007.10.010.CrossRefPubMed

12.

Fair JM, Kiazand A, Varady A, Mahbouba M, Norton L, Rubin GD, Iribarren C, Go AS, Hlatky MA, Fortmann SP: Ethnic differences in coronary artery calcium in a healthy cohort aged 60 to 69 years. Am J Cardiol. 2007, 100: 981-5. 10.1016/j.amjcard.2007.04.038.CrossRefPubMed

13.

Taylor-Piliae RE, Norton LC, Haskell WL, Mahbouda MH, Fair JM, Iribarren C, Hlatky MA, Go AS, Fortmann SP: Validation of a new brief physical activity survey among men and women aged 60-69 years. Am J Epidemiol. 2006, 164: 598-606. 10.1093/aje/kwj248.CrossRefPubMed

14.

Assimes TL, Knowles JW, Priest JR, Basu A, Borchert A, Volcik KA, Grove ML, Tabor HK, Southwick A, Tabibiazar R, Sidney S, Boerwinkle E, Go AS, Iribarren C, Hlatky MA, Fortmann SP, Myers RM, Kuhn H, Risch N, Quertermous T: A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. Atherosclerosis. 2008, 198: 136-44. 10.1016/j.atherosclerosis.2007.09.003.CrossRefPubMed

15.

Sydow K, Fortmann SP, Fair JM, Varady A, Hlatky MA, Go AS, Iribarren C, Tsao PS: Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin Chem. 2009, 56: 111-20.CrossRefPubMed

16.

Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB: Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005, 26: 137-44.CrossRefPubMed

17.

Koenig W, Twardella D, Brenner H, Rothenbacher D: Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006, 26: 1586-93. 10.1161/01.ATV.0000222983.73369.c8.CrossRefPubMed

18.

Blair SN, Haskell WL, P Ho, Paffenbarger RS, Vranizan KM, Farquhar JW, Wood PD: Assessment of habitual physical activity by a seven-day recall in a community survey and controlled experiments. Am J Epidemiol. 1985, 122: 794-804.PubMed

19.

Sallis JF, Haskell WL, Wood PD, Fortmann SP, Rogers T, Blair SN, Paffenbarger RS: Physical activity assessment methodology in the Five-City Project. Am J Epidemiol. 1985, 121: 91-106.PubMed

20.

Block G, Hartman AM, Dresser CM, Carroll MD, Gannon J, Gardner L: A data-based approach to diet questionnaire design and testing. Am J Epidemiol. 1986, 124: 453-69.PubMed

21.

Zakharia F, Basu A, Absher D, Assimes TL, Go AS, Hlatky MA, Iribarren C, Knowles JW, J Li, Narasimhan B, Sidney S, Southwick A, Meyers RM, Quertermous T, Risch N, Tang H: Characterizing the admixed African ancestry of African Americans. Genome Biol. 2009, 10: R141-10.1186/gb-2009-10-12-r141.CrossRefPubMedPubMedCentral

22.

Hoffmann MM, Winkler K, Renner W, Winkelmann BR, Seelhorst U, Wellnitz B, Boehm BO, Marz W: Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study). J Thromb Haemost. 2009, 7: 41-8. 10.1111/j.1538-7836.2008.03216.x.CrossRefPubMed

23.

Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, C Li, Williams DE, Gregg EW, Bainbridge KE, Saydah SH, Geiss LS: Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care. 2009, 32: 287-94.CrossRefPubMedPubMedCentral

24.

Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003, 289: 2363-9. 10.1001/jama.289.18.2363.CrossRefPubMed

25.

Albert MA, Glynn RJ, Wolfert RL, Ridker PM: The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis. 2005, 182: 193-8. 10.1016/j.atherosclerosis.2005.05.006.CrossRefPubMed

26.

El-Saed A, Sekikawa A, Zaky RW, Kadowaki T, Takamiya T, Okamura T, Edmundowicz D, Kita Y, Kuller LH, Ueshima H: Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese men. J Epidemiol. 2007, 17: 179-85. 10.2188/jea.17.179.CrossRefPubMedPubMedCentral

27.

Allison MA, Denenberg JO, Nelson JJ, Natarajan L, Criqui MH: The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients. J Vasc Surg. 2007, 46: 500-6. 10.1016/j.jvs.2007.04.038.CrossRefPubMedPubMedCentral

28.

Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD: Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998, 339: 12-20. 10.1056/NEJM199807023390103.CrossRefPubMed

29.

Schnabel R, Dupuis J, Larson MG, Lunetta KL, Robins SJ, Zhu Y, Rong J, Yin X, Stirnadel HA, Nelson JJ, Wilson PW, Keaney JF, Vasan RS, Benjamin EJ: Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study. Atherosclerosis. 2009, 204: 601-7. 10.1016/j.atherosclerosis.2008.10.030.CrossRefPubMed

30.

Zhang SY, Shibata H, Karino K, Wang BY, Kobayashi S, Masuda J, Nabika T: Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population. Hypertens Res. 2007, 30: 403-9. 10.1291/hypres.30.403.CrossRefPubMed

31.

Wang T, Karino K, Yamasaki M, Zhang Y, Masuda J, Yamaguchi S, Shiwaku K, Nabika T: Effects of G994T in the Lp-PLA2 gene on the plasma oxidized LDL level and carotid intima-media thickness in Japanese: the Shimane study. Am J Hypertens. 2009, 22: 742-7. 10.1038/ajh.2009.70.CrossRefPubMed

32.

Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M: Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis. 2000, 150: 209-16. 10.1016/S0021-9150(99)00385-8.CrossRefPubMed

33.

Lanman RB, Wolfert RL, Fleming JK, Jaffe AS, Roberts WL, Warnick GR, McConnell JP: Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol. 2006, 9: 138-43. 10.1111/j.1520-037X.2006.05547.x.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/11/38/prepub

Title: Racial variation in lipoprotein-associated phospholipase A2in older adults
Authors: Keane K Lee
Stephen P Fortmann
Ann Varady
Joan M Fair
Alan S Go
Thomas Quertermous
Mark A Hlatky
Carlos Iribarren
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: BMC Cardiovascular Disorders / Issue 1/2011
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/1471-2261-11-38

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Racial variation in lipoprotein-associated phospholipase A₂in older adults

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2011

Cardiac arrest associated with sildenafil ingestion in a patient with an abnormal origin of the left coronary artery: case report

Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure

Giant pulmonary artery aneurysm in a patient with vasoreactive pulmonary hypertension: a case report

The relationship between various measures of obesity and arterial stiffness in morbidly obese patients

HEART: heart exercise and remote technologies: A randomized controlled trial study protocol

Awareness, treatment and control of hypertension among the elderly living in their home in Tunisia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page